BioNTech says its InstaDeep acquisition will help it expand its use of artificial intelligence in drug discovery and development. The startup specializes in a type of machine learning called reinforcement learning.
BioNTech is acquiring a preclinical T cell receptor program (TCR) from Medigene, as well as licenses to the biotech’s TCR technologies. The agreement helps BioNTech expand its scope in cancer immunotherapy with a new approach for addressing solid tumors.
Explore top PTSD treatment centers in Arizona, offering personalized care, holistic therapies and expert support to help individuals heal and reclaim their lives.
The company is developing vaccines under the BNT162 program under a partnership with Pfizer. However, Pfizer has declined to accept government funding, and BioNTech said the New York-based drugmaker will continue to cover its own expenses.
The companies also said their Phase II/III study, slated to enroll about 30,000 participants, had already dosed more than 11,000.
The Phase I/II study dosed its first cohort in Germany last week. The trial is enrolling 7,600 participants who will be randomized to receive one of four vaccine candidates or placebo.